Biological agents targeting interleukin-4 receptor alpha (IL-4Rα) in atopic dermatitis (AD) achieved rapid and substantial ...

Patients with atopic dermatitis who receive treatment with dupilumab may be at an increased risk for new-onset vitiligo.

Hand eczema in patients with AD is independently associated with worse QOL measures, with increasing burden seen with increasing hand eczema severity.

Enveda, a clinical-stage biotech company developing first-in-class small-molecules derived from life’s chemistry, today ...

Dr. Lee was compensated for her participation. Board-certified dermatologist Sandra Lee, M.D. (yes, "Dr. Pimple Popper" herself) has spent years helping patients navigate complex sk​in conditions.

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, ...

New research links atopic dermatitis to S1P signalling pathways driving inflammation. Learn how this could shape future ...

A topic dermatitis is a chronic condition that tends to rear its itchy head during certain periods before subsiding — for months, possibly, or even years. It particularly affects the insides of the ...

Exposure to dupilumab is associated with an increased risk of being diagnosed with cutaneous autoimmune diseases in children ...

Researchers explored the relationship between use of glucagon-like peptide-1 receptor agonists among patients with atopic dermatitis and long-term cardiovascular effects.

In patients with moderate atopic dermatitis, the use of Opzelura (ruxolitinib) led to early and sustained improvements in ...